Drug repurposing: A systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Vesterinen, Hanna M ^a   Connick, Peter ^a   Irvine, Cadi M J ^a   Sena, Emily S ^a   Egan, Kieren J ^a   Carmichael, Gary G ^a   Tariq, Afiyah ^a   Pavitt, Sue ^b   Chataway, Jeremy ^c   Macleod, Malcolm R ^a   Chandran, Siddharthan ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; AMILORIDE; ATOMOXETINE; DEXTROMETHORPHAN PLUS QUINIDINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; IBUDILAST; IMIPRAMINE; ISONIAZID; LEVAMISOLE; LINOLEIC ACID; MELATONIN; MEMANTINE; MILACEMIDE; MINOCYCLINE; MODAFINIL; NALTREXONE; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; OXCARBAZEPINE; PIRFENIDONE; POLYUNSATURATED FATTY ACID; RILUZOLE; ROQUINIMEX; SELEGILINE; THIOCTIC ACID; TRANYLCYPROMINE; UNINDEXED DRUG;

ARTICLE; ASTHMA; CLINICAL EVALUATION; DEGENERATIVE DISEASE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG REPOSITIONING; DRUG SCREENING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); DISEASE COURSE; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG REPOSITIONING; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 84928812195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117705     Document Type: Article

References (43)

1. World Health Organization, Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world, 2008. Geneva, Switzerland: World Health Organization; 2008. 51 p.
2. McAlpine D, Ralph Erskine Conrad Memorial Fund. McAlpine's multiple sclerosis Alastair Compston. . . [et al.]. 4th ed. [Edinburgh];;Philadelphia PA: Churchill Livingstone/Elsevier; 2006.
3. Stadelmann C, Wegner C, Brück W. Inflammation, demyelination, and degeneration-recent insights from MS pathology. Biochim Biophys Acta [Internet]. 2011 Feb [cited 2011 Jul 13]; 1812(2):275-82. Available: http://www.ncbi.nlm.nih.gov/pubmed/20637864. doi: 10.1016/j.bbadis.2010.07.007 PMID: 20637864
4. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. The Lancet Neurology [Internet]. 2006 Apr [cited 2011 Jul 6]; 5(4):343-54. Available: http://linkinghub.elsevier.com/retrieve/pii/S1474442206704100. PMID: 16545751
5. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006 Aug; 129(Pt 8):1953-71.
6. Baker D, Gerritsen W, Rundle J, Amor S. Critical appraisal of animal models of multiple sclerosis. Mult Scler. 2011 Jun; 17(6):647-57. doi: 10.1177/1352458511398885 PMID: 21372117
7. Kapoor R. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design. Curr Opin Neurol [Internet]. 2006 Jun [cited 2011 Jul 6]; 19(3):255-9. Available: http://www.ncbi.nlm.nih.gov/pubmed/16702831. PMID: 16702831
8. Mullard A. Could pharma open its drug freezers? Nature Reviews Drug Discovery [Internet]. 2011 Jun [cited 2013 Feb 28]; 10(6):399-400. Available: http://www.nature.com/doifinder/10.1038/nrd3473. doi: 10.1038/nrd3473 PMID: 21629278
9. Mullard A. Drug repurposing programmes get lift off. Nat Rev Drug Discov [Internet]. 2012 Jul [cited 2013 Feb 28]; 11(7):505-6. Available: http://www.nature.com/nrd/journal/v11/n7/full/nrd3776.html. doi: 10.1038/nrd3776 PMID: 22743966
10. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov [Internet]. 2004 Aug [cited 2013 Nov 27]; 3(8):673-83. Available: http://www.nature.com/nrd/journal/v3/n8/full/nrd1468.html. PMID: 15286734
11. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep 20; 367(12):1098-107. PMID: 22992073
12. Meerpohl JJ, Herrle F, Antes G, von Elm E. Scientific Value of Systematic Reviews: Survey of Editors of Core Clinical Journals. PLoS ONE [Internet]. 2012 May 1 [cited 2013 May 27]; 7(5):e35732. Available: http://dx.doi.org/10.1371/journal.pone.0035732. doi: 10.1371/journal.pone.0035732 PMID: 22563469
13. Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can Animal Models of Disease Reliably Inform Human Studies? PLoS Med [Internet]. 2010 Mar [cited 2013 Feb 28]; 7(3). Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846855/. doi: 10.1371/journal.pmed.1000250 PMID: 20361024
14. Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol. 2006 Jul; 176(1- 2):198-215. PMID: 16983747
15. Lassmann H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J Neural Transm. 2011 May; 118(5):747-52. doi: 10.1007/s00702-011-0607-8 PMID: 21373761
16. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998 Dec; 51(12):1235-41. PMID: 10086815
17. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004 Jun 19; 328(7454):1490. PMID: 15205295
18. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004 May; 35(5):1203-8. PMID: 15060322
19. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S, Macleod M, et al. Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler. 2010 Sep; 16(9):1044-55. doi: 10.1177/1352458510379612 PMID: 20685763
20. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, et al. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods. 2014 Jan 15; 221:92-102. doi: 10.1016/j.jneumeth.2013.09.010 PMID: 24099992
21. Sena ES, van der Worp HB, Bath PMW, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010 Mar; 8(3):e1000344. doi: 10.1371/journal.pbio.1000344 PMID: 20361022
22. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, et al. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain. 2013 Jan; 136(Pt 1):106-15.
23. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discov Today. 2005 Jan 15; 10(2):139-47. PMID: 15718163
24. Schwab ME, Buchli AD. Drug research: Plug the real brain drain. Nature [Internet]. 2012 Mar 14 [cited 2013 Feb 28]; 483(7389):267-8. Available from: http://www.nature.com/doifinder/10.1038/483267a doi: 10.1038/483267a PMID: 22422244
25. Cavalla D. Predictive methods in drug repurposing: gold mine or just a bigger haystack? Drug Discovery Today [Internet]. 18(11-12):523-32. Available from: http://www.sciencedirect.com/science/article/pii/S1359644612004321. Accessed: 2013 Nov 25 doi: 10.1016/j.drudis.2013.07.010 PMID: 23891881
26. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009 Dec; 10(17):2897-904. doi: 10.1517/14656560903426189 PMID: 19929708
27. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BMJ, Matsuda K, Landin R, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010 Mar 30; 74(13):1033-40. doi: 10.1212/WNL.0b013e3181d7d651 PMID: 20200338
28. Gibson SB, Bromberg MB. Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside. Semin Neurol. 2012 Jul; 32(3):173-8. doi: 10.1055/s-0032-1329193 PMID: 23117941
29. Chu X-P, Xiong Z-G. Acid-sensing ion channels in pathological conditions. Adv Exp Med Biol. 2013; 961:419-31. doi: 10.1007/978-1-4614-4756-6-36 PMID: 23224900
30. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler. 2005 Apr; 11(2):149-58. PMID: 15794387
31. Kong EKC, Peng L, Chen Y, Yu ACH, Hertz L. Up-regulation of 5-HT2B receptor density and receptormediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res. 2002 Feb; 27(1-2):113-20.
32. Allaman I, Fiumelli H, Magistretti PJ, Martin J-L. Fluoxetine regulates the expression of neurotrophic/ growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl). 2011 Jul; 216 (1):75-84. doi: 10.1007/s00213-011-2190-y PMID: 21301813
33. Mostert JP, Sijens PE, Oudkerk M, De Keyser J. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett. 2006 Jul 10; 402(1-2):22-4.
34. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatr. 2008 Sep; 79(9):1027-31. doi: 10.1136/jnnp.2007.139345 PMID: 18450787
35. Mead GE, Hsieh C-F, Lee R, Kutlubaev MA, Claxton A, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012; 11:CD009286.
36. Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, et al. The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial. ISRN Neurol. 2013; 2013:370943. doi: 10.1155/2013/370943 PMID: 23984093
37. Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci. 2007 Jun; 28(3):156-8. PMID: 17603770
38. Bates D, Cartlidge NE, French JM, Jackson MJ, Nightingale S, Shaw DA, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatr. 1989 Jan; 52(1):18-22. PMID: 2540285
39. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins J, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 21; 486(7403):361-7. doi: 10.1038/nature11159 PMID: 22722194
40. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008 Jul 11; 321(5886):263-6. doi: 10.1126/science.1158140 PMID: 18621671
41. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009 Nov 12; 462(7270):175-81. doi: 10.1038/nature08506 PMID: 19881490
42. Ricigliano VAG, Umeton R, Germinario L, Alma E, Briani M, Di Segni N, et al. Contribution of genomewide association studies to scientific research: a pragmatic approach to evaluate their impact. PLoS ONE. 2013; 8(8):e71198. doi: 10.1371/journal.pone.0071198 PMID: 23967165
43. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther. 2013 Apr; 93(4):335-41. doi: 10.1038/clpt.2013.1 PMID: 23443757